TAKARA BIO INC. Takara Bio Inc. Share Price Deutsche Boerse AG
Equities
TF2
JP3460200003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.55 EUR | +0.77% |
|
+5.65% | -14.94% |
| 05-10 | Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024 | CI |
| 03-18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
| Sales 2025 * | 47.41B 303M 277M 23.34B | Sales 2026 * | 50.55B 323M 296M 24.88B | Capitalization | 142B 906M 829M 69.7B |
|---|---|---|---|---|---|
| Net income 2025 * | 3.66B 23.4M 21.41M 1.8B | Net income 2026 * | 4.28B 27.4M 25.07M 2.11B | EV / Sales 2025 * | 2.99 x |
| Net cash position 2025 * | - 0 0 0 | Net cash position 2026 * | - 0 0 0 | EV / Sales 2026 * | 2.8 x |
| P/E ratio 2025 * |
38.7
x | P/E ratio 2026 * |
33.1
x | Employees | 1,838 |
| Yield 2025 * |
1.53% | Yield 2026 * |
1.7% | Free-Float | 39.09% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.77% | ||
| 1 week | +5.65% | ||
| Current month | +7.38% | ||
| 1 month | +14.91% | ||
| 3 months | +19.09% | ||
| 6 months | -9.66% | ||
| Current year | -14.94% |
1 week
6.45
6.55
1 month
5.606.55
Current year
5.408.25
1 year
5.4011.30
3 years
5.4026.20
5 years
5.4027.80
10 years
5.4027.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 68 | 31/05/14 | |
Koichi Nakao
PSD | President | 62 | 31/03/02 |
Takuya Kakemi
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hisashi Omiya
CHM | Chairman | 81 | 31/03/02 |
Masanobu Kimura
BRD | Director/Board Member | 60 | 30/04/13 |
Koichi Nakao
PSD | President | 62 | 31/03/02 |
| Date | Price | Change |
|---|---|---|
| 17/07/24 | 6.55 | +0.77% |
| 16/07/24 | 6.5 | 0.00% |
| 15/07/24 | 6.5 | 0.00% |
| 12/07/24 | 6.5 | +2.36% |
| 11/07/24 | 6.35 | +2.42% |
Delayed Quote Deutsche Boerse AG, July 17, 2024 at 08:50 pm
More quotes
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Calendar
07/08/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,176
JPY
Average target price
1,567
JPY
Spread / Average Target
+33.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.74% | 47.96B | |
| -0.47% | 42.45B | |
| +43.96% | 41.47B | |
| +25.40% | 31.6B | |
| +17.96% | 28.63B | |
| -4.47% | 28.03B | |
| +50.73% | 14.56B | |
| +42.56% | 14.14B | |
| +1.46% | 12.58B |
- Stock Market
- Equities
- 4974 Stock
- TF2 Stock
